BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 416 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $7,129,032 | +103.2% | 99,498 | +99.6% | 0.00% | +100.0% |
Q1 2024 | $3,508,166 | -31.5% | 49,839 | -24.9% | 0.00% | 0.0% |
Q4 2023 | $5,122,344 | +69.6% | 66,386 | +49.6% | 0.00% | 0.0% |
Q3 2023 | $3,020,606 | +162.8% | 44,375 | +215.1% | 0.00% | – |
Q2 2023 | $1,149,431 | +8.0% | 14,081 | -1.9% | 0.00% | – |
Q1 2023 | $1,064,701 | +22.9% | 14,351 | +37.3% | 0.00% | – |
Q4 2022 | $866,262 | -77.8% | 10,452 | -23.9% | 0.00% | -100.0% |
Q3 2022 | $3,899,000 | +14.6% | 13,728 | +39.9% | 0.00% | +100.0% |
Q2 2022 | $3,401,000 | -67.4% | 9,811 | -59.3% | 0.00% | -66.7% |
Q1 2022 | $10,436,000 | +116.2% | 24,100 | +158.2% | 0.00% | +200.0% |
Q4 2021 | $4,828,000 | -51.1% | 9,333 | -54.2% | 0.00% | -66.7% |
Q3 2021 | $9,870,000 | -59.3% | 20,368 | -62.2% | 0.00% | -66.7% |
Q2 2021 | $24,257,000 | +1046.4% | 53,873 | +872.8% | 0.01% | +800.0% |
Q1 2021 | $2,116,000 | +84.8% | 5,538 | +53.6% | 0.00% | – |
Q4 2020 | $1,145,000 | +131.3% | 3,606 | +80.4% | 0.00% | – |
Q3 2020 | $495,000 | -44.1% | 1,999 | -40.4% | 0.00% | -100.0% |
Q2 2020 | $886,000 | +138.8% | 3,355 | +98.5% | 0.00% | 0.0% |
Q4 2019 | $371,000 | -42.8% | 1,690 | -45.7% | 0.00% | 0.0% |
Q2 2019 | $649,000 | +123.8% | 3,115 | +113.2% | 0.00% | – |
Q1 2019 | $290,000 | -89.1% | 1,461 | -88.8% | 0.00% | -100.0% |
Q3 2018 | $2,666,000 | +581.8% | 13,062 | +333.1% | 0.01% | +400.0% |
Q4 2017 | $391,000 | +26.1% | 3,016 | +17.5% | 0.00% | 0.0% |
Q3 2017 | $310,000 | +13.6% | 2,567 | +2.9% | 0.00% | 0.0% |
Q3 2016 | $273,000 | -41.4% | 2,495 | -39.6% | 0.00% | -50.0% |
Q2 2016 | $466,000 | +91.8% | 4,133 | +53.1% | 0.00% | 0.0% |
Q4 2015 | $243,000 | -69.8% | 2,699 | -69.0% | 0.00% | -60.0% |
Q3 2015 | $804,000 | – | 8,696 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |